Therefore, ADAM9 mRNA has a potential as a biomarker predicting clinical response, and the ADAM9-MICA-NKG2D system may serve as a therapeutic target of HCC immunotherapy. The gene discussed is MICA; the disease is hepatocellular carcinoma.